Raphael J Landovitz
Overview
Explore the profile of Raphael J Landovitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
129
Citations
3358
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Happe M, Lynch R, Fichtenbaum C, Heath S, Koletar S, Landovitz R, et al.
JCI Insight
. 2025 Feb;
10(4).
PMID: 39989458
BACKGROUNDHIV-1-specific broadly neutralizing monoclonal antibodies (bNAbs) have emerged as promising interventions with the potential to effectively treat and prevent HIV-1 infections. We conducted a phase I clinical trial evaluating the...
2.
Blair C, Cambou M, Landovitz R
Annu Rev Med
. 2025 Jan;
76(1):43-56.
PMID: 39869431
Despite rapid advances in the field of HIV prevention and treatment, unacceptably high global HIV incidence rates highlight the ongoing need for effective HIV prevention interventions for populations at risk...
3.
Delany-Moretlwe S, Hanscom B, Guo X, Nkabiito C, Mandima P, Nahirya P, et al.
J Int AIDS Soc
. 2025 Jan;
28(1):e26401.
PMID: 39748218
Introduction: Long-acting injectable cabotegravir (CAB-LA) for pre-exposure prophylaxis significantly reduced HIV acquisition in HPTN 084. We report on the safety and CAB-LA pharmacokinetics in pregnant women during the blinded period...
4.
Edupuganti S, Hurt C, Stephenson K, Huang Y, Paez C, Yu C, et al.
Lancet HIV
. 2024 Dec;
12(1):e13-e25.
PMID: 39667379
Background: Multiple broadly neutralising monoclonal antibodies (mAbs) are in development for HIV-1 prevention. The aim of this trial was to test the PGT121.414.LS and VRC07-523LS mAbs for safety and pharmacokinetics...
5.
Gandhi R, Landovitz R, Sax P, Smith D, Springer S, Gunthard H, et al.
JAMA
. 2024 Dec;
333(7):609-628.
PMID: 39616604
Importance: New data and new antiretroviral drugs and formulations continue to become available for the prevention and management of HIV infection. Objective: To provide updated recommendations for HIV treatment and...
6.
Clement M, Hanscom B, Haines D, Bazan J, Chotirosniramit N, Kofron R, et al.
Clin Infect Dis
. 2024 Nov;
PMID: 39579334
Background: Sexually transmitted infections (STIs) have been shown to facilitate HIV transmission and acquisition. HPTN 083, a global clinical trial, demonstrated superiority of long-acting cabotegravir (CAB-LA) versus daily oral tenofovir...
7.
Reback C, Landovitz R, Benkeser D, Jalali A, Shoptaw S, Li M, et al.
Addict Sci Clin Pract
. 2024 Nov;
19(1):79.
PMID: 39521970
Background: In the United States, most (~ 70%) annual newly diagnosed HIV infections are among substance-using sexual minority men (SMM) and gender minority transgender women (trans women). Trans women and...
8.
Fogel J, Persaud D, Piwowar-Manning E, Richardson P, Szewczyk J, Marzinke M, et al.
AIDS Res Hum Retroviruses
. 2024 Oct;
41(1):30-36.
PMID: 39466048
We evaluated HIV DNA levels in individuals who received long-acting cabotegravir (CAB-LA) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) pre-exposure prophylaxis in the HPTN 083 and 084 trials and had HIV DNA...
9.
Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP Trial
Cooper S, Zhang S, Haines D, Mayer K, Amico K, Landovitz R, et al.
AIDS Behav
. 2024 Jul;
28(11):3710-3718.
PMID: 39083151
Adherence drives efficacy in PrEP clinical trials. We compared drug concentrations and self-reported adherence in HPTN069/ACTG5305, a double-blinded, randomized trial of the safety and tolerability of candidate PrEP regimens that...
10.
Landovitz R, Delany-Moretlwe S, Fogel J, Marzinke M, Piwowar-Manning E, Richardson P, et al.
N Engl J Med
. 2024 Jul;
391(13):1253-1256.
PMID: 39046350
No abstract available.